Logo image of KERX

Keryx Biopharmaceuticals (KERX) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:KERX -

3.36
-0.07 (-2.04%)
Last: 12/12/2018, 8:17:19 PM
3.35
-0.01 (-0.3%)
After Hours: 12/12/2018, 8:17:19 PM

KERX Key Statistics, Chart & Performance

Key Statistics
Market Cap344.00M
Revenue(TTM)94.22M
Net Income(TTM)-90.84M
Shares102.38M
Float101.36M
52 Week High5.98
52 Week Low2.47
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-0.75
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
KERX short term performance overview.The bars show the price performance of KERX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20 -30

KERX long term performance overview.The bars show the price performance of KERX in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of KERX is 3.36 null. In the past month the price increased by 16.26%. In the past year, price decreased by -27.59%.

Keryx Biopharmaceuticals / KERX Daily stock chart

KERX Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to KERX. When comparing the yearly performance of all stocks, KERX is one of the better performing stocks in the market, outperforming 72.17% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

KERX Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to KERX. KERX may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KERX Financial Highlights

Over the last trailing twelve months KERX reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS increased by 20.21% compared to the year before.


Industry RankSector Rank
PM (TTM) -96.41%
ROA -59.85%
ROE 167.54%
Debt/Equity -0.28
Chartmill High Growth Momentum
EPS Q2Q%30%
Sales Q2Q%86.96%
EPS 1Y (TTM)20.21%
Revenue 1Y (TTM)82.98%

KERX Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y34.09%
Revenue Next YearN/A

KERX Ownership

Ownership
Inst Owners0%
Ins Owners2.36%
Short Float %N/A
Short RatioN/A

About KERX

Company Profile

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

Company Info

Keryx Biopharmaceuticals

ONE MARINA PARK DR.

BOSTON MA 02210

CEO: Gregory P. Madison

Phone: 617-466-3500

Keryx Biopharmaceuticals / KERX FAQ

What does KERX do?

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.


What is the stock price of Keryx Biopharmaceuticals today?

The current stock price of KERX is 3.36 null. The price decreased by -2.04% in the last trading session.


Does Keryx Biopharmaceuticals pay dividends?

KERX does not pay a dividend.


How is the ChartMill rating for Keryx Biopharmaceuticals?

KERX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


What is the Price/Earnings (PE) ratio of Keryx Biopharmaceuticals (KERX)?

Keryx Biopharmaceuticals (KERX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).